R&D History

Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection is a therapeutic biological product manufactured by Vanworld Pharmaceutical (Rugao) Company Limited. Clinically, it is mainly indicated for relieving pain, cold sensation, numbness and other symptoms in patients with cervicobrachial syndrome, shoulder-wrist syndrome and lumbago, as well as the treatment of symptomatic neuralgia.

Having been applied in clinical practice for more than two decades, it delivers definite therapeutic effects against various types of neuropathies with a broad spectrum of action and favorable safety profile. This product can not only greatly alleviate or eliminate diverse neuralgia in patients, but also improve comorbidities such as sleep disorders, depression and anxiety, thereby significantly enhancing patients’ quality of life.

01 Initiation of R&D

In 1999, the company officially launched the research and development of Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection.

02 New Drug Certificate Acquisition

A major breakthrough was achieved in drug R&D in 2003, when the company successfully obtained the New Drug Certificate. This milestone meant that Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection was officially recognized by the state as a safe and effective therapeutic product.

03 Therapeutic Efficacy for Neuralgia

In 2005, the company carried out clinical trials targeting neuralgia. The results demonstrated that after two weeks of standardized treatment for symptomatic neuralgia, the overall response rate reached 93.93%. The injection significantly relieved pain symptoms, with no statistically significant difference compared with the positive control group.

04 Update of National Standard and Generic Name

The drug underwent a critical standard adjustment in 2017. Zhao Kai, Member of the Chinese Academy of Engineering and Leader of the National New Drug Review Vaccine Expert Group, put forward a proposal, which received unanimous approval from the Chinese Pharmacopoeia Commission, to revise the generic name to Extracts from Rabbit Skin Inflamed by Vaccinia Virus for Injection.

A new National Standard Approval Document (Standard No.: WS4-(S-001)-2017Z) was issued on June 15 of the same year.

05 New R&D Milestone

In 2023, the company completed Phase III clinical trials of the oral tablet formulation and submitted the marketing registration application, marking a major breakthrough in dosage form innovation of the drug.

06 Indication Expansion for Ischemic Stroke

The company initiated research and development for ischemic stroke indications in 2009.

In July 2017, the Clinical Trial Approval Document was granted by the China Food and Drug Administration (CFDA), officially kicking off clinical research for this new indication. To date, Phase II clinical trials have been completed, with Xuanwu Hospital, Capital Medical University serving as the lead trial center. The trial outcomes were published in the journal iScience (iScience 28, 111621, February 21, 2025).

Thank you for following the official platform of Vanworld! We are committed to providing you with professional, reliable and cutting-edge medical and health information.

Kind Reminder: All content released on this platform is for popular science of health knowledge only, intended to share more health-related information, and shall not replace professional medical diagnosis. Please be sure to consult a qualified doctor and strictly follow medical advice for specific diagnosis and treatment plans.